REFERENCES

1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; 2024. Available from: https://gco.iarc.who.int/today/. [Last accessed on 9 Nov 2026].

2. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29-42.

3. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702-15.

4. Verheij FS, Omer DM, Williams H, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024;42:500-6.

5. Peng H, Wang C, Xiao W, et al. Analysis of clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. J Cancer. 2018;9:2687-92.

6. Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29:3753-60.

7. Miranda J, Causa Andrieu P, Nincevic J, et al. Advances in MRI-based assessment of rectal cancer post-neoadjuvant therapy: a comprehensive review. J Clin Med. 2023;13:172.

8. Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019;20:e253-61.

9. Kather JN, Pearson AT, Halama N, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019;25:1054-6.

10. Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in cancer pathology: a new generation of clinical biomarkers. Br J Cancer. 2021;124:686-96.

11. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467-73.

12. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan - a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

13. Feng L, Liu Z, Li C, et al. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. Lancet Digit Health. 2022;4:e8-17.

14. Foersch S, Glasner C, Woerl AC, et al. Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nat Med. 2023;29:430-9.

15. Jepsen DNM, Høeg H, Bzorek M, et al. Digitally assessed lymphocyte infiltration in rectal cancer biopsies is associated with pathological response to neoadjuvant therapy. Hum Pathol. 2024;144:61-70.

16. Lafarge MW, Domingo E, Sirinukunwattana K, et al. Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy. NPJ Precis Oncol. 2024;8:89.

17. Lou X, Zhou N, Feng L, et al. Deep learning model for predicting the pathological complete response to neoadjuvant chemoradiotherapy of locally advanced rectal cancer. Front Oncol. 2022;12:807264.

18. Shao L, Liu Z, Feng L, et al. Multiparametric MRI and whole slide image-based pretreatment prediction of pathological response to neoadjuvant chemoradiotherapy in rectal cancer: a multicenter radiopathomic study. Ann Surg Oncol. 2020;27:4296-306.

19. Wang A, Ding R, Zhang J, Zhang B, Huang X, Zhou H. Machine learning of histomorphological features predict response to neoadjuvant therapy in locally advanced rectal cancer. J Gastrointest Surg. 2023;27:162-5.

20. Wu Y, Liu X, Liu F, et al. A multi-class classification algorithm based on hematoxylin-eosin staining for neoadjuvant therapy in rectal cancer: a retrospective study. PeerJ. 2023;11:e15408.

21. Zhang F, Yao S, Li Z, et al. Predicting treatment response to neoadjuvant chemoradiotherapy in local advanced rectal cancer by biopsy digital pathology image features. Clin Transl Med. 2020;10:e110.

22. Zhang D, Duan Y, Guo J, et al. Using multi-scale convolutional neural network based on multi-instance learning to predict the efficacy of neoadjuvant chemoradiotherapy for rectal cancer. IEEE J Transl Eng Health Med. 2022;10:4300108.

23. Zhang Y, Huang Y, Xu M, et al. Pathomics-based machine learning models for predicting pathological complete response and prognosis in locally advanced rectal cancer patients post-neoadjuvant chemoradiotherapy: insights from two independent institutional studies. BMC Cancer. 2024;24:1580.

24. Fischer J, Eglinton TW, Richards SJ, Frizelle FA. Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review. Expert Rev Anticancer Ther. 2021;21:489-500.

25. Mbanu P, Saunders MP, Mistry H, et al. Clinical and radiomics prediction of complete response in rectal cancer pre-chemoradiotherapy. Phys Imaging Radiat Oncol. 2022;23:48-53.

26. Tanaka MD, Geubels BM, Grotenhuis BA, et al. Validated pretreatment prediction models for response to neoadjuvant therapy in patients with rectal cancer: a systematic review and critical appraisal. Cancers. 2023;15:3945.

27. Liao Z, Luo D, Tang X, Huang F, Zhang X. MRI-based radiomics for predicting pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis. Front Oncol. 2025;15:1550838.

28. Olawade DB, David-Olawade AC, Adereni T, Egbon E, Teke J, Boussios S. Integrating AI into cancer immunotherapy - a narrative review of current applications and future directions. Diseases. 2025;13:24.